# Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

> **NCT06959108** · PHASE2 · RECRUITING · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 106 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pucotenlimab
- **DRUG:** MRG003

## Key facts

- **NCT ID:** NCT06959108
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2029-06
- **Final completion:** 2029-10
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959108, "Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06959108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*